Novo Nordisk launches Tresiba®

Tresiba®, the new basal insulin developed by Novo Nordisk for the treatment of diabetes, is now commercially available in Bangladesh.
Tresiba® reduces blood glucose levels with a lower risk of night-time hypoglycaemia compared with insulin glargine*,1,2. Tresiba® is a new once-daily basal insulin with a duration of action beyond 42 hours, allowing for flexibility in day-to-day dosing time when needed, without compromising efficacy or risk of hypoglycaemia3,4,5.
A particular problem people with diabetes face, when taking insulin, is suffering a hypoglycaemic episode (an episode of too low blood-sugar)6. Hypoglycaemic episodes are unpleasant and experiencing them might lead to a lower compliance with insulin therapy, leading to increased risk of long-term complications7. Night-time hypoglycaemia is of particular concern for people living with diabetes, as these are often unpredictable and difficult to detect and react upon8.
The launching event of the product was held at the Radisson Blu Water Garden Hotel, Dhaka, in  presence of the Chief Guest from Bangladesh, Prof. A K Azad Khan, President, Diabetic Association of Bangladesh, said a press release.